HRP20120830T1 - Imidazolkarboksamidi - Google Patents

Imidazolkarboksamidi Download PDF

Info

Publication number
HRP20120830T1
HRP20120830T1 HRP20120830AT HRP20120830T HRP20120830T1 HR P20120830 T1 HRP20120830 T1 HR P20120830T1 HR P20120830A T HRP20120830A T HR P20120830AT HR P20120830 T HRP20120830 T HR P20120830T HR P20120830 T1 HRP20120830 T1 HR P20120830T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
methyl
hydrogen
Prior art date
Application number
HRP20120830AT
Other languages
English (en)
Croatian (hr)
Inventor
Albert Khilevich
Bin Liu
Daniel Ray Mayhugh
Jeffrey Michael Schkeryantz
Deyi Zhang
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20120830T1 publication Critical patent/HRP20120830T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91Nitro radicals
    • C07D233/92Nitro radicals attached in position 4 or 5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Developing Agents For Electrophotography (AREA)
HRP20120830AT 2008-07-18 2009-07-14 Imidazolkarboksamidi HRP20120830T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8177408P 2008-07-18 2008-07-18
PCT/US2009/050440 WO2010009062A1 (en) 2008-07-18 2009-07-14 Imidazole carboxamides

Publications (1)

Publication Number Publication Date
HRP20120830T1 true HRP20120830T1 (hr) 2012-11-30

Family

ID=41128155

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120830AT HRP20120830T1 (hr) 2008-07-18 2009-07-14 Imidazolkarboksamidi

Country Status (19)

Country Link
US (1) US7754742B2 (https=)
EP (1) EP2318375B1 (https=)
JP (1) JP5379227B2 (https=)
KR (1) KR101287713B1 (https=)
CN (1) CN102099344B (https=)
AR (1) AR074631A1 (https=)
BR (1) BRPI0915977A2 (https=)
CA (1) CA2731215C (https=)
CY (1) CY1113315T1 (https=)
DK (1) DK2318375T3 (https=)
EA (1) EA018434B1 (https=)
ES (1) ES2393243T3 (https=)
HR (1) HRP20120830T1 (https=)
MX (1) MX2011000611A (https=)
PL (1) PL2318375T3 (https=)
PT (1) PT2318375E (https=)
SI (1) SI2318375T1 (https=)
TW (1) TW201006801A (https=)
WO (1) WO2010009062A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
CN101801930B (zh) 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-二取代的-4-苯基-1h-吡啶-2-酮
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
EP2681196B1 (en) 2011-03-04 2015-09-09 Life Technologies Corporation Compounds and methods for conjugation of biomolecules
CA2830027C (en) 2011-03-31 2016-04-26 Pfizer Inc. Novel bicyclic pyridinones
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
MX368391B (es) 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
WO2016169902A1 (en) * 2015-04-23 2016-10-27 F. Hoffmann-La Roche Ag Tetrazole derivatives for use in the treatment of psychiatric disorders
CN104788694B (zh) * 2015-04-29 2018-06-08 江苏亚宝绝缘材料股份有限公司 一种超低收缩率的聚酰亚胺薄膜
WO2017060202A1 (en) 2015-10-06 2017-04-13 F. Hoffmann-La Roche Ag Triazole derivatives
CN108473462B (zh) 2016-02-02 2021-06-22 豪夫迈·罗氏有限公司 作为eaat3抑制剂的吡唑-吡啶衍生物
WO2017202896A1 (en) 2016-05-27 2017-11-30 F. Hoffmann-La Roche Ag Pyrazol compounds as eaat3 inhibitors
JP7068277B2 (ja) 2016-10-14 2022-05-16 エフ.ホフマン-ラ ロシュ アーゲー Eaat3阻害剤としてのイミダゾール化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE7897T1 (de) 1979-09-05 1984-06-15 Glaxo Group Limited Phenol-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
US4666928A (en) 1984-08-30 1987-05-19 Merck Frosst Canada, Ind. Propylphenoxy pyridine carboxylates as leukotriene antagonists
AU643140B2 (en) 1991-05-31 1993-11-04 Sumitomo Pharmaceuticals Company, Limited Leukotriene B4 antagonist
US6800651B2 (en) 2000-02-03 2004-10-05 Eli Lilly And Company Potentiators of glutamate receptors
AU2003262805A1 (en) 2002-08-26 2004-03-11 Merck & Co., Inc. Acetophenone potentiators of metabotropic glutamate receptors
CA2574956A1 (en) 2004-07-30 2006-02-09 Merck & Co., Inc. Heterocyclic acetophenone potentiators of metabotropic glutamate receptors
US20080312286A1 (en) 2004-07-30 2008-12-18 Pinkerton Anthony B Indanone Potentiators of Metabotropic Glutamate Receptors
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US20080096935A1 (en) 2004-10-25 2008-04-24 Pinkerton Anthony B Heterocyclic Indanone Potentiators of Metabotropic Glutamate Receptors
DK1817301T3 (da) * 2004-11-22 2012-02-27 Lilly Co Eli Forstærkere af glutamat-receptorer
JP2008525478A (ja) 2004-12-27 2008-07-17 アストラゼネカ アクチボラグ 神経系及び精神医学系障害の治療のための代謝共役型グルタミン酸受容体アゴニストとしてのピラゾロン化合物
JP5031745B2 (ja) 2005-08-12 2012-09-26 アストラゼネカ アクチボラグ 代謝型グルタミン酸受容体増強性イソインドロン

Also Published As

Publication number Publication date
US7754742B2 (en) 2010-07-13
PL2318375T3 (pl) 2013-02-28
KR101287713B1 (ko) 2013-07-23
BRPI0915977A2 (pt) 2018-10-30
JP2011528658A (ja) 2011-11-24
EP2318375B1 (en) 2012-09-19
SI2318375T1 (sl) 2012-11-30
CY1113315T1 (el) 2016-04-13
TW201006801A (en) 2010-02-16
AU2009271105A1 (en) 2010-01-21
WO2010009062A1 (en) 2010-01-21
EA201170227A1 (ru) 2011-06-30
AR074631A1 (es) 2011-02-02
ES2393243T3 (es) 2012-12-19
DK2318375T3 (da) 2012-10-08
CN102099344B (zh) 2013-10-30
EP2318375A1 (en) 2011-05-11
EA018434B1 (ru) 2013-07-30
CA2731215A1 (en) 2010-01-21
KR20110022676A (ko) 2011-03-07
CA2731215C (en) 2013-08-27
CN102099344A (zh) 2011-06-15
JP5379227B2 (ja) 2013-12-25
US20100016373A1 (en) 2010-01-21
PT2318375E (pt) 2012-10-22
MX2011000611A (es) 2011-03-01

Similar Documents

Publication Publication Date Title
HRP20120830T1 (hr) Imidazolkarboksamidi
JP2011528658A5 (https=)
HRP20180528T1 (hr) Derivati naftiridina, korisni kao antagonisti alfa-v-beta-6 integrina
HRP20170403T1 (hr) SUPSTITUIRANI BENZOAZEPINI KAO MODULATORI TOLL-u SLIČNIH RECEPTORA
ME02840B (me) Spojevi fenoksietilpiperidina
HRP20221389T1 (hr) Inhibitori bromodomena
HRP20170695T1 (hr) Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka
MX2011011484A (es) Derivados de isoxazol-piridina como moduladores del acido gamma-aminobutirico.
HRP20120505T1 (hr) Supstituirani n fenilmetil oksoprolin amidi kao antagonisti receptora p x i postupci njihove upotrebe
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
HRP20171028T1 (hr) Indolski i indazolski spojevi koji aktiviraju ampk
HRP20090077A2 (hr) Modulatori farmakokinetičkih svojstava terapeutika
HRP20150941T1 (hr) Derivati aminodihidrotiazina kao inhibitori bace u lijeäśenju alzheimerove bolesti
HRP20140611T1 (hr) Inhibitori kinaze p70 s6
HRP20170025T1 (hr) Derivati tetrahidropirolotiazina kao inhibitori bace
HRP20240157T1 (hr) Deuterirani derivati lanifibranora
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
WO2014093583A3 (en) Synthetic methods for preparing 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, other salt forms of this compound and intermediates thereof
JP2017528506A5 (https=)
NZ594641A (en) Pyrazole derivatives used as ccr4 receptor antagonists
JP2012512863A5 (https=)
MX2011011303A (es) Derivados de isoxazol.
HRP20211429T1 (hr) Derivati sobetiroma
RU2019135834A (ru) Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила
RU2008150616A (ru) Производные 5-фенилтиазол-2-илмочевины и применение в качестве ингибиторов киназы pi3